Acumen Pharmaceuticals, Inc. (ABOS)
Develops an experimental Alzheimer's drug targeting toxic brain proteins.
$2.28+0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+68.9%
The outlook
Acumen Pharmaceuticals is trading at $2.28, sitting well below both its 50- and 200-day moving averages. Analysts uniformly rate it a Strong Buy with an average target implying significant upside from current levels. The stock sits roughly midway in its 52-week range, with data leaning bullish overall.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range45% of the way from its 52-week low to high
Price targetAvg target +225% vs current price
Analyst price target
~12-month · 5 analysts$7.40average target+224.6% vs now
Now $2.28
Low $4.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$164.7M
52-wk high
$3.60
52-wk low
$1.19
50-day avg
$2.39
200-day avg
$2.35
Trailing P/E
—